The pharmaceutical industry is witnessing one of the most consequential patent cliff events in decades. Semaglutide, the active pharmaceutical ingredient behind Novo Nordisk blockbuster Ozempic and Wegovy, has lost patent protection in China, India, Canada, and Brazil since early 2026.
The original semaglutide compound patent expired on March 20, 2026. While Novo Nordisk has defended its US portfolio with 320 patent applications, the international picture is far more open. Canada patents expired January 4, 2026, triggering immediate generic filings from Sandoz, Apotex, Teva, and Aspen. India and China followed in March, with at least 17 generic candidates in Phase 3 in China and over 50 brands preparing to launch in India.
For API suppliers and contract manufacturers, the patent cliff translates into tangible demand. Semaglutide is a complex peptide API requiring specialized solid-phase synthesis. The number of qualified manufacturers globally remains limited, creating pricing power for established peptide CDMOs.
China has at least 17 generic semaglutide candidates in Phase 3. Chinese peptide manufacturers are scaling capacity. In India, over 50 brands are preparing to launch. Generic liraglutide already shows a 70 percent price drop in sensitive markets.
For pharmaceutical suppliers, the patent cliff offers three priorities: secure early supply agreements, invest in quality infrastructure, and diversify beyond semaglutide to the broader GLP-1 pipeline.
